PARP1 and neoplasm: As the effective dose and radiation absorbed doses in normal tissues are relevant for radionuclide therapy to achieve optimal outcome [23], we evaluated the effects of injected mass (μg) and molar activity on tumour and organ uptake of [18F]olaparib, as a model for other radiolabelled PARP inhibitors.